专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1993021936A1 LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF 审中-公开
标题翻译： c-kit接收者的配体及其使用方法
公开(公告)号：WO1993021936A1
公开(公告)日：1993-11-11
申请号：PCT/US1993003640
申请日：1993-04-16
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , BESMER, Peter , BUCK, Jochen , MOORE, Malcolm, A., S. , NOCKA, Karl
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K35/16
CPC分类号： C07K14/715 , A61K38/18 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/202 , A61K48/00 , C07K14/71 , A61K2300/00
摘要： A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.
摘要翻译：提供了包含通过申请人纯化或由申请人的重组方法与其他造血因子组合产生的c-kit配体（KL）和药学上可接受的载体的药物组合物，以及治疗患者的方法，其包括向患者施用本发明的药物组合物。本发明提供了使用c-kit配体（KL）和纯化的c-kit配体（KL）多肽或其可溶性片段和其他造血因子的组合疗法。它还提供单独使用KL或联合治疗的离体使用KL方法和组合物。还描述了突变的KL拮抗剂。这样的拮抗剂也可以是小分子。还描述了作为治疗剂的KL的反义核酸。最后，描述了利用KL在生殖细胞，肥大细胞和黑素细胞中的作用的组合物和方法。

2. 发明申请

WO1992003459A1 LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF 审中-公开
标题翻译： c-kit接收者的配体及其使用方法
公开(公告)号：WO1992003459A1
公开(公告)日：1992-03-05
申请号：PCT/US1991006130
申请日：1991-08-27
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , BESMER, Peter , NOCKA, Karl , BUCK, Jochen , MOORE, Malcolm, A., S.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： C07H15/12
CPC分类号： A61K31/7072 , A61K38/00 , A61K38/193 , A61K38/202 , C07K14/475 , C07K14/52 , C07K14/705 , C07K14/71 , C07K14/715 , C07K16/22 , C12N15/87 , A61K2300/00
摘要： The invention provides an isolated nucleic acid molecule which encodes an amino acid sequence corresponding to a c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof. A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.
摘要翻译：本发明提供了分离的核酸分子，其编码对应于c-kit配体（KL）和纯化的c-kit配体（KL）多肽或其可溶性片段的氨基酸序列。进一步提供包含通过申请人纯化或由申请人的重组方法产生的c-kit配体（KL）和药学上可接受的载体的药物组合物以及治疗患者的方法，所述方法包括向患者施用本发明的药物组合物。

3. 发明申请

WO1993022267A1 NOVEL RETINOL DERIVATIVES AND USES THEREOF 审中-公开
标题翻译：新型维生素D衍生物及其用途
公开(公告)号：WO1993022267A1
公开(公告)日：1993-11-11
申请号：PCT/US1993004323
申请日：1993-05-06
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY ... , BUCK, Jochen , HAMMERLING, Ulrich , DERGUINI, Fadila , NAKANISHI, Koji
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY ...
IPC分类号： C07C43/15
CPC分类号： C12N15/67 , C07B2200/09 , C07C403/08 , C07C403/10 , C07C403/12 , C07C403/20 , C07C2601/14 , C07C2601/16 , C07D303/14 , C07F7/1804 , C12N5/065 , C12N2501/385 , C12P23/00
摘要： The present invention provides a purified retinoid compound characterized by a molecular mass of about 320 daltons and an atomic composition of C20H32O3. The present invention also provides a purified retinoid compound having structure (I), wherein the configuration of the C7, C9, and C11 double bond independently is Z or E and the absolute configuration at C13 and C14 is independently R or S; wherein R1 is alkyl, alkyl halide, alcohol, ester, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, acyl halide, amide, nitrile, or amine; R2 and R3 are independently hydroxyl, halide, alkoxy, ester, alkyl, alcohol, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, nitrile, amine, azide, alkyl halide, acid halide, acid azide, or amide; or wherein R2 and R3, or R1 and R2 are replaced by a 13,14-oxirane or a 14,15-oxirane group, respectively. Also provided by this invention is a pharmaceutical composition which comprises the compound above and a pharmaceutically acceptable carrier. This invention further provides a growth medium comprising the compound above at a concentration effective to enhance cell growth. Additionally, the present invention provides a method of enhancing the growth of a cell, a method for enhancing an immune response in a subject, and a method for enhancing transcription of a gene regulated by retinoid in a cell.
摘要翻译：本发明提供一种纯化的类视色素化合物，其特征在于分子量为约320道尔顿，原子组成为C20H32O3。本发明还提供具有结构（I）的纯化维甲酸化合物，其中C7，C9和C11双键的构型独立地为Z或E，C13和C14的绝对构型独立地为R或S; 其中R1是烷基，烷基卤，醇，酯，醚，醛，酮，羧酸，羧酸酯，酰卤，酰胺，腈或胺; R2和R3独立地是羟基，卤素，烷氧基，酯，烷基，醇，醚，醛，酮，羧酸，羧酸酯，腈，胺，叠氮化物，烷基卤，酰卤，酸叠氮化物或酰胺; 或其中R2和R3，或R1和R2分别被13,14-环氧乙烷或14,15-环氧乙烷基团取代。本发明还提供了包含上述化合物和药学上可接受的载体的药物组合物。本发明进一步提供包含上述化合物的生物培养基，其浓度有效地增强细胞生长。另外，本发明提供增强细胞生长的方法，增强受试者的免疫应答的方法，以及增强细胞中类视黄醇调节基因转录的方法。

4. 发明申请

WO1992018639A1 NOVEL RETRO-ALPHA-RETINOL DERIVATIVES AND USES OF RETRO-ALPHA-RETINOL 审中-公开
标题翻译：新型改性阿尔法 - 雷丁醇衍生物及其用途
公开(公告)号：WO1992018639A1
公开(公告)日：1992-10-29
申请号：PCT/US1992002904
申请日：1992-04-09
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY ... , BUCK, Jochen , HAMMERLING, Ulrich , DERGUINI, Fadila , NAKANISHI, Koji
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY ...
IPC分类号： C12P17/02
CPC分类号： C12P23/00 , A61K31/07 , A61K31/075 , A61K31/202 , C07B2200/09 , C07C403/08 , C07C403/10 , C07C403/12 , C07C2601/14 , C07C2601/16 , C07D303/14 , C07F7/1804 , C12N1/38 , C12N5/065 , C12N15/67 , C12N2501/385 , A61K2300/00
摘要： This invention provides a purified retro-retinoid compound characterized by a molecular mass of about 302 daltons. Also provided by this invention is a method of enhancing the growth of a cell in a vitamin A reduced environment which comprises contacting the cell with an effective growth enhancing amount of a compound having a structure (I), wherein the configuration of the C6, C8, C10 and C12 double bond independently is Z or E and the absolute configuration at C-14 is independently R or S; wherein R1 is alkyl, alkyl halide, alcohol, ester, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, acid halide, amide, nitrile, or amine; and wherein R2 is hydroxyl, halide, alkoxy, ester, alkyl, alcohol, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, nitrile, amine, azide, alkyl halide, acid halide, acid azide, or amide; or wherein R1 and R2 are replaced by a 14, 15-oxirane group; and wherein the retro structure is alpha or gamma. Further provided are a method for enhancing transcription of a gene regulated by retinoid in a cell, or a method for enhancing an immune response in a subject.
摘要翻译：本发明提供了一种以分子质量为约302道尔顿为特征的纯化的后视色素化合物。本发明还提供一种增强维生素A还原环境中细胞生长的方法，其包括使细胞与有效生长增加量的具有结构（I）的化合物接触，其中C6，C8的构型，C10和C12双键独立地为Z或E，C-14的绝对构型独立地为R或S; 其中R1是烷基，烷基卤，醇，酯，醚，醛，酮，羧酸，羧酸酯，酰卤，酰胺，腈或胺; 烷基，醇，醚，醛，酮，羧酸，羧酸酯，腈，胺，叠氮化物，烷基卤，酰卤，叠氮化物或酰胺; 或其中R 1和R 2被14,15-环氧乙烷基团取代; 并且其中所述复古结构是α或γ。还提供了增强细胞中类视黄醇调节基因转录的方法，或增强受试者的免疫应答的方法。

5. 发明申请

WO1997039745A1 USE OF INHALED RETINOIDS IN THE PREVENTION OF CANCER 审中-公开
标题翻译：在预防癌症中使用吸入反应物
公开(公告)号：WO1997039745A1
公开(公告)日：1997-10-30
申请号：PCT/US1997005409
申请日：1997-04-21
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , TONG, William, P. , WARRELL, Raymond, P.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K31/045
CPC分类号： A61K9/008 , A61K31/07 , A61K31/167 , A61K31/192 , A61K31/203 , A61K47/18
摘要： Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the prevention of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
摘要翻译：通过吸入来施用类维生素A来克服由全身给药引起的慢性毒性问题，并且可以使类视黄醇治疗作为预防呼吸道上皮癌，特别是与烟草使用有关的癌症的选择。类维生素A通过吸入个体的呼吸道作为空气传播组合物施用，其具有计量剂量气雾产生吸入器，其中类视黄醇溶解在药学上可接受的氯氟烃推进剂和烷基胺增溶剂的组合中。

6. 发明申请

WO1997034634A1 SINGLE CHAIN FV CONSTRUCTS OF ANTI-GANGLIOSIDE GD2 ANTIBODIES 审中-公开
标题翻译：抗链球菌GD2抗体的单链FV构建
公开(公告)号：WO1997034634A1
公开(公告)日：1997-09-25
申请号：PCT/US1997004427
申请日：1997-03-20
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , CHEUNG, Nai-Kong, V. , LARSON, Steven, M. , GUO, Hong-Fen , RIVLIN, Ken , SADELAIN, Michel
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K39/395
CPC分类号： C07K16/3084 , A61K47/6898 , A61K47/6899 , B82Y5/00 , C07K14/36 , C07K14/70517 , C07K16/30
摘要： Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-GD2 antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target GD2-producing tumor cells.
摘要翻译：重组抗体构建体包含抗GD2抗体的重链和轻链的可变区。这些抗体构建体可以偶联到诸如放射性标记的标记物或蛋白质例如链霉亲和素或前药转化酶，用于成像或治疗应用。抗体构建体也可以被转导入T细胞以产生靶向产生GD2的肿瘤细胞的T细胞群体。

7. 发明申请

WO1997027858A1 COMBINATION THERAPY METHOD FOR TREATING CANCER USING EDATREXATE AND A TAXANE DERIVATIVE, E.G. PACLITAXEL 审中-公开
标题翻译：用于治疗癌症的组合治疗方法和药物衍生物，E.G. 紫杉醇
公开(公告)号：WO1997027858A1
公开(公告)日：1997-08-07
申请号：PCT/US1997000947
申请日：1997-01-29
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , FENNELLY, David, W. , SIROTNAK, Francis, M.
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K31/505
CPC分类号： A61K31/519 , A61K31/505 , A61K31/335 , A61K2300/00
摘要： This invention provides combination therapy methods, pharmaceutical combinations and compositions for inducing tumor cell regression in cancer patients, particularly metastatic breast cancer patients. The combination methods, combinations and compositions employ both edatrexate and a taxane (e.g. Paclitaxel) which are administered simultaneously or sequentially. The combination therapy described here permits the administration of unusually high doses of edatrexate.
摘要翻译：本发明提供了用于在癌症患者，特别是转移性乳腺癌患者中诱导肿瘤细胞退化的组合疗法，药物组合和组合物。组合方法，组合和组合物使用同时或顺序施用的依达曲斯和紫杉烷（例如紫杉醇）。这里描述的联合疗法允许施用异常高剂量的依达曲塞。

8. 发明申请

WO1997021729A1 METHODS AND COMPOSITIONS FOR MODULATING VESICLE RELEASE 审中-公开
标题翻译：调制VESICLE RELEASE的方法和组合物
公开(公告)号：WO1997021729A1
公开(公告)日：1997-06-19
申请号：PCT/US1996019661
申请日：1996-12-12
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , SCHIAVO, Giampietro , ROTHMAN, James, E. , SÖLLNER, Thomas, H.
IPC分类号： C07K14/47
CPC分类号： C07K14/705 , C07K14/47 , C07K2319/00
摘要： This invention provides methods and compositions useful for modulating synaptic transmission. The compositions of this invention are complexes comprised of various combinations of proteins, such as tagmin, beta -SNAP, NSF, alpha -SNAP, and SNAREs involved in docking and fusion of synaptic vesicles to membranes. In addition, this invention relates to complexes of tagmin and special phospholipids (phosphatidyl inositols) which are a component of membranes involved in the secretory process. These complexes are useful for identifying other substances which may modulate synaptic transmission.
摘要翻译：本发明提供了可用于调节突触传递的方法和组合物。本发明的组合物是由各种蛋白质组合组成的复合物，例如tagmin，β-SNAP，NSF，α-NAP和涉及突触小泡与膜的对接和融合的SNARE。此外，本发明涉及tagmin和作为分泌过程涉及的膜的组分的特殊磷脂（磷脂酰肌醇）的复合物。这些复合物可用于鉴定可能调节突触传递的其他物质。

9. 发明申请

WO1997006821A1 HEAT SHOCK PROTEIN-BASED VACCINES AND IMMUNOTHERAPIES 审中-公开
标题翻译：基于热休克蛋白的疫苗和免疫治疗
公开(公告)号：WO1997006821A1
公开(公告)日：1997-02-27
申请号：PCT/US1996013363
申请日：1996-08-16
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , ROTHMAN, James, E. , HARTL, F., Ulrich , HOE, Mee, H. , HOUGHTON, Alan , TAKEUCHI, Yoshizumi , MAYHEW, Mark
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
IPC分类号： A61K39/00
CPC分类号： C07K7/06 , A61K38/00 , A61K39/0005 , A61K39/0011 , A61K39/02 , A61K39/12 , A61K47/646 , A61K47/65 , A61K47/6901 , A61K48/00 , A61K2039/5152 , A61K2039/5156 , A61K2039/53 , A61K2039/6043 , A61K2039/622 , A61K2039/625 , C07K7/08 , C07K14/47 , C12N2710/20034 , Y10S530/828
摘要： The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious diseases and cancers.
摘要翻译：本发明涉及用于在受试者中诱导免疫应答的方法和组合物，其中所述受试者与一种或多种所定义的靶抗原组合施用有效量的至少一种热休克蛋白。这些方法和组合物可用于治疗感染性疾病和癌症。

10. 发明申请

WO1996034005A1 SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBR1 AND USES THEREOF 审中-公开
标题翻译：由单克隆抗体MBR1定义的与乳腺癌相关的抗原的合成及其用途
公开(公告)号：WO1996034005A1
公开(公告)日：1996-10-31
申请号：PCT/US1996006109
申请日：1996-04-26
申请人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
发明人： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , DANISHEFSKY, Samuel, J. , BILODEAU, Mark, T. , HU, Shuang, Hua , PARK, Tae, Kyo , RANDOLPH, John, T. , KIM, In, Jong , LIVINGSTON, Philip, O.
IPC分类号： C07H15/24
CPC分类号： C07H15/10 , A61K38/00 , A61K39/0011 , C07H3/06 , C07H15/18 , C07H17/02 , C07K1/04 , C07K9/005 , C07K16/3015 , C07K16/44
摘要： The present invention provides a process for synthesizing a compound having structure (I), wherein R is H, as well as related oligosaccharides useful as a vaccine for inducing antibodies to human breast cancer cells in an adjuvant therapy therefor.
摘要翻译：本发明提供了用于合成具有结构（I）的化合物的方法，其中R是H，以及可用作用于在其辅助治疗中诱导人乳腺癌细胞的抗体的疫苗的相关寡糖。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式